Palo Alto – December 18, 2017 – Cooley advised Unchained Labs on its acquisition of Belgium-based life sciences company Trinean and its concurrent Series C financing round. Cooley partner Mark Weeks led the team advising Unchained Labs.

Trinean's DropSense systems measure protein, DNA and RNA concentration in biologics and genomics samples. The system can measure up to 96 high concentration protein samples in 5 minutes.

“These products are a perfect strategic fit for Unchained Labs,” said Tim Harkness, founder and CEO of Unchained Labs, in a news release. “Concentration measurement is central to everything our customers do and DropSense96 is the only product in the world that does it for biologics at high concentration with high-throughput.”

Based in Pleasanton, California, Unchained Labs helps biologics researchers break free from tools that just don't cut it. The acquisition of Trinean marks the fifth acquisition on which Cooley has advised Unchained Labs since helping form the company in 2014.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.